Salarius stockholders re-elect directors, approve say-on-pay, ratify auditor at annual meeting

Decoy Therapeutics Inc.

Two Class III directors re-elected: Tess Burleson (141,974 for) and Paul Lammers (145,485 for).
Non-binding advisory vote on named executive officer compensation approved (135,949 for, 18,637 against).
Ratification of Ernst & Young LLP as independent auditor for FY 2024 approved (496,239 for, 59,576 against).
Quorum of 39.7% (572,540 of 1,441,157 shares) present at December 20, 2024 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.